From boosting children’s eye health awareness to celebrating our first OptPE affix and refreshing member learning - here’s how we shaped the profession in early 2025.
The Medicine & Healthcare products Regulatory Agency (MHRA) has approved the first licensed low-dose atropine (LDA) treatment for slowing the progression of childhood myopia.